Abbott Laboratories stock steadies as medical devices and diagnostics underpin growth
Published on 07/22/2026 at 03:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories (ISIN US0028241000) reported quarterly revenue of more than $10 billion and delivered double digit growth in adjusted earnings per share compared with the prior year, underscoring the earnings power behind Abbott Laboratories stock according to recent company disclosures. The latest reported quarter in 2026 showed that the healthcare group continued to benefit from expanding medical devices and a resilient diagnostics portfolio, based on the companys published financial information.
Revenue above $10 billion in latest quarter
According to Abbott Laboratories published quarterly results for 2026, total company revenue exceeded $10 billion in the latest reported quarter, illustrating the scale of the diversified healthcare portfolio. Within that total, management highlighted that the business achieved high single digit organic sales growth compared with the same quarter a year earlier, reflecting contributions from medical devices, diagnostics, nutrition, and established pharmaceuticals.
The same disclosures indicated that adjusted earnings per share increased at a double digit rate year over year in that 2026 quarter, supported by operating leverage and a favorable product mix. Adjusted operating margin improved compared with the prior year period, helping Abbott Laboratories convert revenue growth into faster profit expansion.
Medical devices deliver high single digit growth
In the medical devices segment, Abbott Laboratories reported high single digit organic sales growth in the 2026 quarter versus the prior year, backed by continued uptake of minimally invasive cardiovascular and electrophysiology products. The company noted that cardiology-related devices and diabetes care contributed meaningfully to that growth profile, offsetting more mature areas within the portfolio.
Diagnostics revenue in the same 2026 quarter was broadly stable compared with the year earlier period after adjusting for lower contributions from prior coronavirus testing. Core laboratory and molecular diagnostics remained the largest contributors to the diagnostics top line, helping Abbott Laboratories maintain a diversified base of recurring revenue in hospitals and laboratories worldwide.
Further background on Abbott Laboratories
Investors can review additional details on Abbott Laboratories financial performance, product pipeline, and corporate governance in dedicated company and regulatory materials.
Nutrition and established pharmaceuticals add balance
The nutrition business, which includes pediatric and adult nutrition brands, contributed several billion dollars of revenue in the latest fiscal year and returned to growth after prior supply challenges, according to Abbott Laboratories published annual figures. Sales in this division increased year over year in the most recently reported fiscal period, adding another leg of support to the companys diversified top line.
Abbott Laboratories established pharmaceuticals division, focused on branded generics in emerging markets, also generated revenue of several billion dollars in the latest fiscal year and delivered year over year growth as demand improved across key geographies. This division helps the group balance more cyclical capital equipment exposure in other segments with prescription medicine sales in faster growing markets.
Dividend growth and capital allocation
Abbott Laboratories has a long history of returning cash to shareholders through dividends, and the company reported that it has raised its dividend payout for more than four consecutive decades. The annual dividend per share increased again in the latest fiscal year, reflecting managements confidence in the companys cash flow generation.
In addition to dividends, Abbott Laboratories continues to invest heavily in research and development to support new product introductions. Annual R&D spending runs into the billions of dollars, underpinning pipeline projects across cardiovascular devices, diabetes care, diagnostics platforms, and nutrition science. For long term investors, the balance between shareholder returns and growth investment is a central element of the Abbott Laboratories equity story.
Continuous glucose monitoring as a growth driver
One of Abbott Laboratories most visible product lines is its continuous glucose monitoring system for people living with diabetes, which has seen strong adoption worldwide. Company disclosures indicate that revenue from diabetes care, including continuous glucose monitoring, has been growing at a double digit rate year over year in recent reporting periods as more patients and healthcare systems embrace sensor based glucose tracking.
The installed base of users for these glucose monitoring systems has expanded into the millions globally, supporting recurring sensor sales and positioning Abbott Laboratories as a key player in the diabetes technology market. This business segment is part of the medical devices division and contributes to the high single digit organic sales growth reported for that segment in the 2026 quarter.
Abbott Laboratories stock and recent trading context
Abbott Laboratories stock trades on the New York Stock Exchange and reflects investor expectations for steady mid single digit to high single digit revenue growth combined with operating margin expansion over time. The companys market capitalization stands in the tens of billions of dollars, underscoring its role as a large constituent of major healthcare and blue chip equity indices.
Recent trading in Abbott Laboratories stock has mirrored broader healthcare sector dynamics, with investors weighing defensive cash flow characteristics against valuation levels after a long period of strong performance. For portfolio managers, the combination of dividend growth, recurring revenue in diagnostics and devices, and exposure to secular health trends such as aging populations and chronic disease management continues to shape the investment case.
Abbott Laboratories key facts
- Company: Abbott Laboratories
- ISIN: US0028241000
- Ticker: NYSE: ABT
- Trading venue: NYSE
- Sector / Industry: Health Care / Health Care Equipment and Supplies
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
